Immutep (IMM) Stock Price, News & Analysis

Company Overview

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2.15 million shs
• Average Volume: N/A
• Market Capitalization: $465.79 million
• P/E Ratio: N/A
• Dividend Yield: 6.41%
• Price Target: N/A
• Consensus Rating: N/A

IMM Stock Analysis - Frequently Asked Questions

How were Immutep's earnings last quarter?

Immutep Limited (ASX:IMM) posted its quarterly earnings results on Wednesday, February, 27th. The company reported $0.00 EPS for the quarter. Immutep had a negative net margin of 1,138.04% and a negative trailing twelve-month return on equity of 34.61%.

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immutep investors own include ICL Group (ICL), Geron (GERN), Enphase Energy (ENPH), Immutep (IMMP), Seres Therapeutics (MCRB), OPKO Health (OPK) and Albireo Pharma (ALBO).

Company Calendar

• Last Earnings: 2/27/2019
• Today: 4/27/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:IMM
• CIK: N/A
• Web: www.primabiomed.com.au
• Phone: 61 2 8315 7003
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -5.92
• Net Income: $-42,720,000.00
• Net Margins: -1,138.04%
• Pretax Margin: N/A
• Return on Equity: -34.61%
• Return on Assets: -16.67%

Debt

• Debt-to-Equity Ratio: 0.90
• Current Ratio: 13.81
• Quick Ratio: 13.78

Sales & Book Value

• Annual Sales: $3.84 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 2.83
• Book Value: A$0.16 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,450,000,000
• Free Float: N/A
• Market Cap: $465.79 million
• Optionable: Not Optionable
• Beta: 1.93